Business Wire

New Genome Study of B. longum subsp. longum by Morinaga Milk May Explain the Species' Wide Distribution across All Ages

Del

Bifidobacterium longum is one of only a handful of species of gut bacteria that is widely present among people of all ages, including infants, adults and the elderly.1,2 Today, Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, announced the results of a groundbreaking new genome study, in collaboration with the SFI Research Centre APC Microbiome Ireland, that may explain why.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180214005461/en/

(Fig.1) Distribution of gut microbiota in healthy Japanese subjects (Graphic: Business Wire)

(Fig.1) Distribution of gut microbiota in healthy Japanese subjects (Graphic: Business Wire)

The human gut is colonized by a collection of microbes (microbiome) which play an integral role in human health, by helping us digest our food, produce certain vitamins, regulate our immune system, and protect us against pathogenic bacteria. This current study revealed that one bacterial species, B. longum subsp. longum, demonstrates a wide variation in its genes that increases its competitiveness in the gut environment, because its genome adapts to the changing diet of each generation. In addition, it suggests that B. longum subsp. longum is extensively transmitted between relatives, and that such transmission does not occur only between mothers and infants, as previously believed, but also between other family members and even across three generations.3

Study Overview
For the study, a total of 453 fecal samples were collected from healthy Japanese subjects aged 0 to 104 years, as a means of measuring the bacterial species present in the gut. In total, 871 different bacterial species were detected (Fig.1), but only three species (Blautia wexlerae, Streptococcus salivarius and Bifidobacterium longum) were found to be present in more than 50% of the subjects across all generations.

This finding highlights the broad distribution of B. longum across the human lifespan. In order to identify the mechanism that allows a specific species to be so ubiquitous, Morinaga, in collaboration with the SFI Research Centre APC Microbiome Ireland at the National University of Ireland, Cork, performed a comparative genome analysis on various strains of B. longum subsp. longum to determine genetic differences among strains isolated from people of varying ages.

B. longum subsp. longum Strains Separated into Seven Clusters
Comparative analyses involving 145 B. longum representatives obtained from Japanese subjects, including 32 publicly available genomes, showed that B. longum subsp. longum strains can be grouped into seven clusters depending on the presence of prophage (i.e. viral material) and/or a megaplasmid (i.e. genetic material being present outside of the bacterial chromosome).

No correlation was observed between isolated strains and subject age, although a significant negative correlation was found between the number of identified genes present in the strains and subject age. This suggests that B. longum subsp. longum strains isolated from younger subjects possess, on average, a higher number of genes compared to the ones from older subjects. Researchers performed further investigation to identify genes in each strain isolated from different age groups, and as a result, gene families were classified into four groups: infant, adult, elderly-predominant gene families, and genes that exhibit no relationship with subjects age (Fig.2).

Infant-associated Strains More Adapted to Utilize Carbohydrates Found in Human Milk
Researchers frequently found strains in B. longum subsp. longum from younger subjects, which possess genetic code that is related to sugar utilization, including that of the sugar sialic acid which is one of the components of Human Milk Oligosaccharides (HMOs) that are found in breast milk. This characteristic may be an adaptive strategy of B. longum to survive the infant gut environment by utilizing components from the mother’s breast milk.

Elderly-associated Strains More Adapted to Utilize Insoluble Fiber Found in Vegetables
Researchers also observed a high number of strains in B. longum subsp. longum isolated from elderly subjects that contain unique genetic information thought to encode extracellular α-L-arabinofuranosidases (Arabinofuranosidase cluster2 in Fig.2). These enzymes are able to break down complex sugars that are present in plant material, such as vegetables and cereals, all of which contain a high proportion of insoluble fiber. Elderly Japanese people are reported to eat much more vegetables than younger people4, so this genetic trait to digest fiber-containing foods may allow B. longum to persist in the elderly gut.

In addition, two clusters of genes indicative of how bacteria respond to environmental stress were found in higher numbers among strains of B. longum subsp. longum isolated from elderly subjects, including the heat shock protein HSP20.5 Heat shock proteins are produced to help an organism respond to stress, such as extreme heat, oxygen exposure and starvation. It is reasonable to assume that strains with the ability to respond to stress are better able to adapt and survive.

Certain Strains Have Been Transmitted Between Father and Child, Husband and Wife, and Even Across Three Generations
Several B. longum subsp. longum strains, which had been isolated from many different members of the same family, were shown to contain an essentially identical genetic content. This finding suggests that these strains had been transmitted between various family members, not only between mother and child, which has been previously reported.6

“It is a remarkable finding that not only was transmission between mother and child observed, but also between father and child and even between husband and wife,” stated Dr. Toshitaka Odamaki, Manager of Microbiota Research Dept. at Next Generation Science Institute of Morinaga and lead researcher of the study. “This is also the first report of a particular strain of gut microbiota that appears to have been transmitted across three generations in a family, for instance, between a grandmother, mother, and infant,” he added.

“We assume this variety of genes and high transfer level of the bacterial species within families is the survival strategy of B. longum subsp. longum and is key to its wide distribution across the human lifespan,” explained Dr. Odamaki. “This report could provide a promising foundation for future research aimed at identifying the best probiotic candidates at each key life stage,” he continued.

APC Microbiome Ireland is very interested in how the human microbiota changes over the life stages, in response to exposure to different environmental factors such as habitual diet, antibiotic exposure, and levels of stress”, said Prof Douwe van Sinderen, project leader at APC Microbiome Ireland. He furthermore emphasized the attraction of such a joint scientific effort: “This was a particularly fruitful and gratifying collaborative project with an industry partner, Morinaga, because we were able to join our complementary skills and know-how allowing us to generate insights that we would otherwise not have been able to obtain on our own”.

Dr. Odamaki from Morinaga discussed these findings at the IPA World Congress + Probiota Barcelona held in Barcelona, Spain on February 7th -9th, 2018.

About Morinaga
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan. Morinaga started research on bifidobacteria in the 1960s, inspired by the fact that bifidobacteria are the predominant bacteria residing in the intestines of breast-fed infants. In 1969, Morinaga isolated its flagship strain Bifidobacterium longum BB536 from an infant. Morinaga excels in innovative technology and offers various dairy products and other beneficial functional ingredients to customers around the world.

ABOUT APC MICROBIOME IRELAND
APC Microbiome Ireland (APC; http://apc.ucc.ie) is a world leading research institute which was formed in 2003 with funding from Science Foundation Ireland and in conjunction with key industry partners. It represents a seamless collaboration between University College Cork and Teagasc (the Irish Agriculture and Food Development Authority).It is widely recognised that the gut microbiota plays an important role in human health and has become one of the most dynamic, complex and exciting areas of research in both food and pharmaceutical arenas. Over the last decade the APC has established itself as one of the leading global centres in gut microbiota research. The APC has made several landmark discoveries and has published over 1,700 research articles in peer-reviewed journals, generating many journal covers and associated editorials. The APC comprises over 300 individuals, from the scientific Principal Investigators (the APC Faculty) funded by the partner Institutions, the management team, and a dedicated group of research scientists, research assistants and postgraduate students.

References
1.  

Turroni et al., Applied and environmental microbiology (2009)

2.

Francoise Gavini, Microb. Ecol. Health Dis (2001)

3.

Odamaki et al., Scientific Reports (2018)

4. National Health and Nutrition Survey 2015
5.

Ventura et al., Appl. Environ. Microbiol (2007)

6.

Makino et al., Appl. Environ. Microbiol (2011)

Contact information

Morinaga Milk Industry Co., Ltd.
Mai Nozawa, +81-3-3798-0152
m-nozawa@morinagamilk.co.jp
http://www.morinagamilk.co.jp/english/

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ABB Showcases World-Leading e-Vehicle Fast Chargers and Launches AI Readiness Index at Hannover22.4.2018 10:00Pressemelding

ABB spotlighted its world-leading Terra HP family of fast chargers for electric vehicles at Hannover Messe, the biggest global industrial trade fair. By operating at powers of up to 350 kilowatts and adding as much as 300 kilometers of range to an electric vehicle in just 12 minutes, the Terra HP family of chargers have made electric cars more appealing for consumers by enabling them to refresh the batteries in about the same time required for filling up a petrol-powered car. Terra HP chargers are being installed around the world, and they have been selected for use by Electrify America, the biggest electric vehicle infrastructure project to date in the United States. ABB, whose broad array of digitally driven technologies for electric-power management are used by utilities and businesses worldwide, is also a global leader in industrial automation and robots enabled by artificial intelligence (AI). Demonstrating its commitment to helping the international community address the opportun

PSE: APM Forum 2018 Focus on Digitalisation for the Process Industries20.4.2018 15:13Pressemelding

At the 2018 Advanced Process Modelling (APM) Forum this week, process industry organisations presented on digital design and operations applications ranging from accelerating development of the next generation of pharmaceuticals to realising millions of dollars per year in increased profit for large process plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180420005517/en/ Ben Weinstein, head of R&D Product and Process Systems Modeling at Procter & Gamble, delivers the keynote speech on how digital design techniques are used systematically to accelerate innovation in P&G. (Photo: Business Wire) Introducing the conference, Prof. Costas Pantelides, MD of conference host Process Systems Enterprise (PSE), described the current wave of digitalisation as the culmination of many years of advanced modelling and IT development. “This is a time of extraordinary opportunities for the process industries” he said. Keynote speaker Ma

Aperta Provides Electronic Funds Transfer (EFT) in Cayman Islands20.4.2018 14:01Pressemelding

Once again, the Aperta Active Clearing System (ACS) has delivered the mechanism for a country to implement a world-class electronic payment processing environment to maximize a national payments system’s efficiency, effectiveness, security and control. Aperta partnered with the Cayman Islands ACH Operator (Prism Services (Cayman) Ltd.) and local commercial banks to deliver a new Electronic Funds Transfer system. The old process of banks swapping files in a wide-variety of standards and settling bilaterally has been replaced with a common system and standards, employing international-standard secure file transfer protocol, allowing participants to monitor real time net settlement and collateral positions via a secure portal. The Cayman Islands Automated Clearinghouse (CIACH) links all six of the country’s banks and provides the central clearing and settlement mechanism for banks to exchange direct debit and direct credit transactions seamlessly across the country. It is functionally NAC

FII Tech Growth Invests in SECO20.4.2018 13:39Pressemelding

FII Tech Growth, a fund managed by Fondo Italiano d’Investimento SGR, announces today its second investment in SECO SpA, one of the European leaders in the embedded electronics market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180420005413/en/ (Photo: SECO) SECO, headquartered in Arezzo, Tuscany, with subsidiaries in the U.S.A., Germany and Taiwan, was founded in 1979 by entrepreneurs Daniele Conti and Luciano Secciani. The company designs and manufactures micro-computers and integrated systems for industrial applications. With more than 250 employees, SECO supports customers with a worldwide presence such as Cimbali, Esaote, Technogym and Vimar, and generated revenue in excess of Euro 50 million in 2017. The ability to offer innovative solutions by using cutting-edge technologies has allowed SECO to grow steadily over time. The company developed a network of collaborations with universities and research centres La Sapi

Schlumberger Announces First-Quarter 2018 Results20.4.2018 11:05Pressemelding

Schlumberger Limited (NYSE:SLB) today reported results for the first quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Mar. 31, 2018 Dec. 31, 2017 Mar. 31, 2017 Sequential Year-on-year Revenue $7,829 $8,179 $6,894 -4% 14% Pretax operating income $974 $1,155 $757 -16% 29% Pretax operating margin 12.4% 14.1% 11.0% -169 bps 145 bps Net income (loss) - GAAP basis $525 $(2,255) $279 n/m 88% Net income, excluding charges & credits* $525 $668 $347 -21% 51% Diluted EPS (loss per share) - GAAP basis $0.38 $(1.63) $0.20 n/m 90% Diluted EPS, excluding charges & credits* $0.38 $0.48 $0.25 -21% 52% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. n/m = not meaningful Schlumberger Chairman and CEO Paal Kibsgaard commented, “As forecast, our results in the first quarter of 2018 largely reflected transitory factors, with seasonal reductions in activity in the Northern Hemisphere and planned project startup costs

Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases20.4.2018 10:30Pressemelding

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases. This collaboration capitalizes on Biogen’s expertise in neuroscience research and drug development and Ionis’ leadership in RNA targeted therapies with the goal of developing a broad pipeline of investigational therapies. It builds upon a productive collaboration that produced SPINRAZA, the first and only approved treatment for patients with spinal muscular atrophy. Today, April 20, 2018, Biogen and Ionis will host company conference calls and webcasts to discuss the new collaboration. Full webcast details can be found below. Under the terms of the collaboration, Biogen will pay Ionis $1 billion in cash, which will include $625 million to purchase 11,501,153 shares of Ionis common stock at a price of $54.34 per share, at an appr